Background:
Primary pediatric brain tumors are the most prevalent type of childhood tumors and the most common cause of cancer death among children. However, there is insufficient literature regarding the use of novel chemotherapy agents to treat such tumors.
Therefore, the purpose of this study is to evaluate the effectiveness of Irinotecan-based chemotherapy regimen for the treatment of primary brain tumors as well as minimizing morbidity and mortality rates.